Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
gptkb:fulvestrant
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EM07
|
| gptkbp:brand |
gptkb:Piqray
|
| gptkbp:CASNumber |
1217486-61-7
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C19H22F3N5O2
|
| gptkbp:hasUNII |
8LJ08WK8ZL
|
| gptkbp:indication |
HR-positive, HER2-negative advanced or metastatic breast cancer
|
| gptkbp:mechanismOfAction |
PI3K alpha inhibitor
|
| gptkbp:molecularWeight |
441.41 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL2219416
50909890 DB12001 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash hyperglycemia |
| gptkbp:synonym |
gptkb:Alpelisib
|
| gptkbp:target |
gptkb:PIK3CA
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Alpelisib
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
BYL719
|